Table 5. Summary of human radiomics studies using ICC for feature quantification.
| First author, year | Disease | Patient number/feature number/ICC sample size | Quantification factor | Satisfactory feature rate | ICC threshold |
|---|---|---|---|---|---|
| CT | |||||
| Bogowicz et al., 2016 (105) | Lung cancer, HNC | 11+11/315/11+11 | Discretization | ~40% | 0.9 |
| Foy et al., 2018 (116) | HNC | 39/12/39 | Radiomics calculation | 33% | 0.9 |
| Soufi et al., 2018 (22) | Lung cancer | 162+143/432/305 | Discretization | NE | 0.75 |
| Lee et al., 2019 (63) | Lung nodule | 194 patients (260 scans) /252/114 patients (180 scans) | Discretization | ~9.5–11.5% | 0.7 |
| Zwanenburg et al., 2019 (28) | Lung cancer, HNC | 31+19/4,032/31+19 | Discretization | ~10–65% (FBW); 10–40%(FBN) | 0.9 |
| Park et al., 2020 (109) | Bladder cancer | 83/55/83 | Discretization | NE | 0.75 |
| MRI | |||||
| Duron et al., 2019 (91) | Lachrymal gland tumors, breast cancer | 74+30/69/74+30 | Discretization | NE | 0.8 |
| Schwier et al., 2019 (111) | Prostate cancer | 15/1,120/15 | Discretization | NE | 0.85 |
| Traverso et al., 2020 (95) | Cervical cancer | 81/552/81 | Discretization | NE | 0.9 |
| Pandey et al., 2021 (41) | Healthy | 87+4+8/93/4+8 | Harmonization | 60.33% (GM); 62% (WM) | 0.5 |
| Shiri et al., 2020 (44) | GBM | 17/26,295,192/17 | Discretization | NE | 0.95 |
| Suter et al., 2020 (64) | GBM | 63+76/8,327/19 | Discretization | NE | 0.85 |
| PET | |||||
| Tixier et al., 2012 (117) | HNC | 16/25/16 | Discretization | NE | NA |
| Leijenaar et al., 2015 (118) | Lung cancer | 35/44/35 | Discretization | NE | NA |
| Lu et al., 2016 (101) | NPC | 40/88/40 | Discretization | 23% (18F-FDG), 21% (11C-choline) | 0.8 |
| Altazi et al., 2017 (65) | Cervical cancer | 88/79/80 | Discretization | 18% (GLCM and GLRLM) | 0.9 |
| Bogowicz et al., 2017 (119) | HNC | 128+50/649/178 | Feature implementation | 12% | 0.8 |
| Lv et al., 2018 (120) | NPC | 106/57/106 | Averaging, symmetry, distance | NE | 0.8 |
| Branchini et al., 2019 (114) | Pediatric | 21/106/21 | Discretization | NE | 0.9 |
| PET, MRI | |||||
| Yang et al., 2020 (104) | NPC | 21/540/21 | Discretization | 12.96% (PET and T2), 11.30% (DWI) | 0.95 |
NA, not available or not clear; NE, could not be simply extracted due to comprehensive results, see the reference for detail; HNC, head and neck cancer; FBW, fixed bin width; FBN, fixed bin number; GM, gray matter; WM, white matter; NPC, nasopharyngeal carcinoma; GBM, glioblastoma multiforme; GLCM, gray level co-occurrence matrix; GLRLM, gray level run length matrix; DWI, diffusion-weighted imaging.